Today: 19 July 2026
UiPath (PATH) stock slides after CEO share sale filing as S&P MidCap 400 entry takes effect
3 January 2026
1 min read

UiPath (PATH) stock slides after CEO share sale filing as S&P MidCap 400 entry takes effect

NEW YORK, January 3, 2026, 07:07 ET — Market closed

  • UiPath shares fell about 3% in the last session despite its first day as an S&P MidCap 400 constituent
  • A regulatory filing showed CEO Daniel Dines sold 45,000 shares under a pre-arranged trading plan
  • Traders are watching for follow-through from index-related flows and key U.S. data next week

UiPath Inc (PATH) shares fell nearly 3% on Friday, closing at $15.88, after a filing showed CEO Daniel Dines sold stock and as the automation software maker began trading as a new addition to the S&P MidCap 400. The shares swung between $15.50 and $16.85, with about 44.1 million shares changing hands.

The timing matters because index changes can trigger large, mechanical trades by funds that track the benchmark, often amplifying volume and short-term swings even without new fundamentals.

Insider sales can also draw attention around index reshuffles, when liquidity is shifting and investors are recalibrating positions at the turn of the year.

In a Form 4 filed with U.S. regulators, Dines reported selling 45,000 Class A shares on Jan. 2 at an average price of $16.3846, with transactions ranging from $16.18 to $16.59. The filing said the shares were sold “in compliance with a qualified selling plan” under Rule 10b5-1. UiPath, Inc.

Rule 10b5-1 plans are pre-set trading instructions that allow executives to buy or sell shares on a schedule, reducing the risk of trading on material nonpublic information.

S&P Dow Jones Indices said UiPath replaced Synovus Financial in the S&P MidCap 400 effective before the open on Jan. 2, a move tied to Synovus’ pending acquisition by Pinnacle Financial Partners.

The S&P MidCap 400 tracks 400 mid-sized U.S. companies and is widely followed by passive funds and exchange-traded funds that aim to mirror its holdings, which can create forced buying and selling around index changes.

UiPath sells software that helps companies automate repetitive business processes — often called robotic process automation — and its shares can trade like other growth-oriented software names when interest-rate expectations shift.

In the broader market on Friday, the Dow rose 0.66% and the S&P 500 gained 0.19%, while the Nasdaq slipped 0.03%, as U.S. stocks rebounded to start 2026 after a late-December stumble.

UiPath lagged the broader tape, with the heavy turnover pointing to a mix of index-related repositioning and discretionary selling after the effective date arrived.

Before the next session, traders will focus on the next batch of U.S. macro data, starting with the Institute for Supply Management’s manufacturing report for December, due Monday at 10 a.m. ET, which can move rate expectations that often drive software valuations.

Later in the week, the U.S. Labor Department is scheduled to release the December employment report on Friday at 8:30 a.m. ET, followed by December consumer inflation data on Jan. 13, both key markers for the path of interest rates.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • CSL Recovers A$16 Billion in Value, Trails Plasma Sector Gains This Week
    July 19, 2026, 3:25 PM EDT. CSL Limited (ASX:CSL) finished July 17 at A$123.32, rising 1.12% on the session and 0.35% for the week, recovering 37% from its 52-week low at A$90 and regaining roughly A$16 billion in valuation. However, CSL underperformed plasma specialists Grifols SA (+1.95%) and Takeda Pharmaceutical (+2.26%) in weekly movement. Trading volume for CSL on Friday came in 14% under its average as 1.62 million shares changed hands. The full-year financial results are due August 18. Still 55% beneath its 52-week peak, CSL's market value stands at A$59.06 billion. The group forecasts FY26 revenues near US$15.2 billion and NPATA of about US$3.1 billion, while a US$5 billion impairment remains subject to audit and board sign-off.
UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead
Previous Story

UnitedHealth stock rises today as 2026 opens; UNH holds gains after hours with earnings ahead

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window
Next Story

Blackbaud stock slides nearly 6% to start 2026 as investors eye jobs data and mid-Feb earnings window

Go toTop